NO320194B1 - Vitronektin reseptor antagonister, anvendelse og fremstilling derav samt farmasoytisk sammensetning - Google Patents

Vitronektin reseptor antagonister, anvendelse og fremstilling derav samt farmasoytisk sammensetning Download PDF

Info

Publication number
NO320194B1
NO320194B1 NO19991590A NO991590A NO320194B1 NO 320194 B1 NO320194 B1 NO 320194B1 NO 19991590 A NO19991590 A NO 19991590A NO 991590 A NO991590 A NO 991590A NO 320194 B1 NO320194 B1 NO 320194B1
Authority
NO
Norway
Prior art keywords
tetrahydro
oxo
benzazepine
propyloxy
acetic acid
Prior art date
Application number
NO19991590A
Other languages
English (en)
Norwegian (no)
Other versions
NO991590D0 (no
NO991590L (no
Inventor
James Francis Callahan
Richard Mccullock Keenan
Russell Donovan Cousins
Irene Nijole Uzinskas
Chet Kwon
William Henry Miller
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO991590D0 publication Critical patent/NO991590D0/no
Publication of NO991590L publication Critical patent/NO991590L/no
Publication of NO320194B1 publication Critical patent/NO320194B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO19991590A 1996-10-02 1999-03-31 Vitronektin reseptor antagonister, anvendelse og fremstilling derav samt farmasoytisk sammensetning NO320194B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2732096P 1996-10-02 1996-10-02
US4377697P 1997-04-11 1997-04-11
PCT/US1997/018001 WO1998014192A1 (en) 1996-10-02 1997-10-01 Vitronectin receptor antagonists

Publications (3)

Publication Number Publication Date
NO991590D0 NO991590D0 (no) 1999-03-31
NO991590L NO991590L (no) 1999-05-31
NO320194B1 true NO320194B1 (no) 2005-11-14

Family

ID=26702318

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19991590A NO320194B1 (no) 1996-10-02 1999-03-31 Vitronektin reseptor antagonister, anvendelse og fremstilling derav samt farmasoytisk sammensetning

Country Status (37)

Country Link
EP (1) EP0957917B1 (pt)
JP (2) JP4491072B2 (pt)
KR (1) KR100589578B1 (pt)
CN (1) CN1114403C (pt)
AP (1) AP1463A (pt)
AR (1) AR008878A1 (pt)
AT (1) ATE312089T1 (pt)
AU (1) AU733417B2 (pt)
BG (1) BG64581B1 (pt)
BR (1) BR9712248B1 (pt)
CA (1) CA2267224C (pt)
CO (1) CO4900046A1 (pt)
CY (1) CY2576B1 (pt)
CZ (1) CZ299076B6 (pt)
DE (1) DE69734833T2 (pt)
DK (1) DK0957917T3 (pt)
DZ (1) DZ2320A1 (pt)
EA (1) EA002419B1 (pt)
ES (1) ES2252775T3 (pt)
HK (1) HK1023730A1 (pt)
HU (1) HU229221B1 (pt)
ID (1) ID19623A (pt)
IL (1) IL129243A (pt)
MA (1) MA24361A1 (pt)
MY (1) MY137606A (pt)
NO (1) NO320194B1 (pt)
NZ (1) NZ334953A (pt)
PE (1) PE10499A1 (pt)
PL (1) PL190859B1 (pt)
RO (1) RO119881B1 (pt)
SA (1) SA98180936B1 (pt)
SK (1) SK285029B6 (pt)
TR (1) TR199900737T2 (pt)
TW (1) TW487702B (pt)
UA (1) UA60311C2 (pt)
UY (2) UY24735A1 (pt)
WO (1) WO1998014192A1 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA60311C2 (uk) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція
TW527355B (en) 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
CN1273529A (zh) * 1997-09-24 2000-11-15 史密丝克莱恩比彻姆公司 玻连蛋白受体拮抗剂
JP2002500162A (ja) * 1997-09-24 2002-01-08 スミスクライン・ビーチャム・コーポレイション ビトロネクチン受容体アンタゴニスト
US6372719B1 (en) * 1998-03-04 2002-04-16 Jay Cunningham ανβ3 integrin antagonists in combination with chemotherapeutic agents
DE19842415A1 (de) 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
KR20010110310A (ko) * 1998-12-23 2001-12-12 로저 에이. 윌리암스 종양 치료에 사이클로옥시게나제-2 억제제와 하나 이상의항종양제를 조합치료법으로서 사용하는 방법
EP1150965A4 (en) * 1999-02-03 2002-05-15 Merck & Co Inc BENZAZEPINE DERIVATIVES FOR USE AS ANTAGONISTS OF THE INTEGRIN ALPHA-V RECEPTOR
EP1398033B1 (en) * 1999-04-30 2009-06-17 The Regents Of The University Of Michigan Use of benzodiazepines for treating autoimmune diseases, inflammations, neoplasies, viral infections and atherosclerosis
WO2001010867A1 (en) * 1999-08-06 2001-02-15 Smithkline Beecham Corporation Vitronectin receptor antagonists useful for the treatment of strokes
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
DE10028575A1 (de) 2000-06-14 2002-03-14 Basf Ag Integrinliganden
DE10027514A1 (de) * 2000-06-06 2002-01-03 Basf Ag Liganden von Integrinrezeptoren
FR2806082B1 (fr) * 2000-03-07 2002-05-17 Adir Nouveaux composes bicycliques antagonistes des recepteurs de la vitronectine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ATE530183T1 (de) 2001-01-29 2011-11-15 Ortho Mcneil Pharm Inc Substituierte indole und ihre verwendung als integrin-antagonisten
ATE417612T1 (de) * 2001-04-10 2009-01-15 Smithkline Beecham Corp Verfahren zur unterdrückung von adhäsionsbildung
SE0101386D0 (sv) 2001-04-20 2001-04-20 Astrazeneca Ab New compounds
EP1387688A2 (en) 2001-05-03 2004-02-11 Merck & Co., Inc. Benzazepinone alpha v integrin receptor antagonists
KR101159061B1 (ko) 2001-10-22 2012-06-22 더 스크립스 리서치 인스티튜트 항체 표적화 화합물
GB0215867D0 (en) * 2002-07-09 2002-08-14 Glaxosmithkline Spa Novel method and compounds
EP1628949A4 (en) * 2003-04-04 2008-07-02 Smithkline Beecham Corp PROCESS AND INTERMEDIATE PRODUCTS FOR PREPARING BENZAZEPINES
AU2012216372B2 (en) * 2004-04-02 2015-01-22 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin
ES2411965T3 (es) * 2004-04-02 2013-07-09 The Regents Of The University Of California Métodos y composiciones para tratar y prevenir enfermedad asociada con integrina alfa V beta 5
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
EP1841406A4 (en) * 2004-12-21 2008-06-25 Smithkline Beecham Corp METHOD AND FORMULATIONS
NZ568075A (en) * 2005-11-29 2010-12-24 Smithkline Beecham Corp Treatment of ocular neovascular disorders such as macular degeneration, angoid streaks, uveitis and macular edema
WO2009061448A2 (en) 2007-11-08 2009-05-14 The General Hospital Corporation Methods and compositions for the treatment of proteinuric diseases
AU2008321770B2 (en) * 2007-11-16 2012-09-06 Ube Industries, Ltd. Benzazepinone compound
US8076475B2 (en) * 2008-03-06 2011-12-13 Glaxosmithkline Llc Process
EP2395992A2 (en) 2009-02-10 2011-12-21 The Scripps Research Institute Chemically programmed vaccination
US20120095215A1 (en) * 2009-03-30 2012-04-19 Ube Industries, Ltd. Medical composition for treatment or prophylaxis of eye diseases
JP5572996B2 (ja) * 2009-05-15 2014-08-20 宇部興産株式会社 ベンズアゼピノン化合物を有効成分として含有する医薬
US10087252B2 (en) 2009-07-24 2018-10-02 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with αvβ5 integrin
EP2501387B1 (en) 2009-11-17 2016-07-27 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
EP2325194A1 (en) * 2009-11-24 2011-05-25 Glycotope GmbH Process for the purification of glycoproteins
AU2015265571A1 (en) 2014-05-30 2016-11-17 Pfizer Inc. Carbonitrile derivatives as selective androgen receptor modulators
KR20230004662A (ko) * 2020-04-26 2023-01-06 지앙수 엔화 파마수티컬 컴퍼니 리미티드 1,5-디하이드로-2,4-벤조디아제핀-3-온 유도체 및 이의 응용
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0674623B1 (en) * 1992-12-21 2003-04-09 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
AU702661B2 (en) * 1994-06-29 1999-02-25 Smithkline Beecham Corporation Vitronectin receptor antagonists
EP0762882A4 (en) * 1994-06-29 2002-09-11 Smithkline Beecham Corp Vibronectin Receptor Antagonists
JPH10504825A (ja) * 1994-08-22 1998-05-12 スミスクライン・ビーチャム・コーポレイション 二環式化合物
WO1996026190A1 (en) * 1995-02-22 1996-08-29 Smithkline Beecham Corporation Integrin receptor antagonists
UA60311C2 (uk) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція

Also Published As

Publication number Publication date
AU733417B2 (en) 2001-05-17
TR199900737T2 (xx) 1999-07-21
DE69734833T2 (de) 2006-07-13
CN1238689A (zh) 1999-12-15
EA002419B1 (ru) 2002-04-25
IL129243A (en) 2004-07-25
RO119881B1 (ro) 2005-05-30
ATE312089T1 (de) 2005-12-15
PL190859B1 (pl) 2006-02-28
HUP9903769A2 (hu) 2000-03-28
CZ113299A3 (cs) 2000-03-15
NZ334953A (en) 2000-01-28
ID19623A (id) 1998-07-23
UA60311C2 (uk) 2003-10-15
EA199900356A1 (ru) 2000-02-28
EP0957917B1 (en) 2005-12-07
CA2267224C (en) 2007-03-13
AR008878A1 (es) 2000-02-23
PL332674A1 (en) 1999-09-27
HU229221B1 (en) 2013-09-30
JP2010006838A (ja) 2010-01-14
EP0957917A1 (en) 1999-11-24
ES2252775T3 (es) 2006-05-16
CZ299076B6 (cs) 2008-04-16
CA2267224A1 (en) 1998-04-09
IL129243A0 (en) 2000-02-17
HUP9903769A3 (en) 2000-07-28
UY24935A1 (es) 2001-07-31
DK0957917T3 (da) 2006-04-18
PE10499A1 (es) 1999-03-27
EP0957917A4 (en) 2002-05-15
CY2576B1 (en) 2008-07-02
DE69734833D1 (de) 2006-01-12
WO1998014192A1 (en) 1998-04-09
MY137606A (en) 2009-02-27
SK285029B6 (sk) 2006-04-06
CN1114403C (zh) 2003-07-16
KR100589578B1 (ko) 2006-06-15
UY24735A1 (es) 1998-03-30
NO991590D0 (no) 1999-03-31
MA24361A1 (fr) 1998-07-01
AP9901493A0 (en) 1999-03-31
HK1023730A1 (en) 2000-09-22
JP4491072B2 (ja) 2010-06-30
BR9712248A (pt) 1999-08-24
TW487702B (en) 2002-05-21
KR20000048816A (ko) 2000-07-25
BG103299A (en) 2000-01-31
AU4746297A (en) 1998-04-24
JP2001501936A (ja) 2001-02-13
BR9712248B1 (pt) 2010-06-29
BG64581B1 (bg) 2005-08-31
DZ2320A1 (fr) 2002-12-28
SA98180936B1 (ar) 2006-05-30
CO4900046A1 (es) 2000-03-27
NO991590L (no) 1999-05-31
SK42599A3 (en) 1999-12-10
AP1463A (en) 2005-09-10

Similar Documents

Publication Publication Date Title
NO320194B1 (no) Vitronektin reseptor antagonister, anvendelse og fremstilling derav samt farmasoytisk sammensetning
US6239138B1 (en) Vitronectin receptor antagonist
CA2303846A1 (en) Vitronectin receptor antagonist
SK13292000A3 (sk) Antagonisty vitronektínového receptora, spôsob ich výroby, farmaceutický prostriedok s ich obsahom, ich použitie a medziprodukty
CA2304000A1 (en) Vitronectin receptor antagonist
US6825188B2 (en) Vitronectin receptor antagonists
US6458814B1 (en) Vitronectin receptor antagonists
US20020123487A1 (en) Vitronectin receptor antagonist
US20020128257A1 (en) Vitronectin receptor antagonist
MXPA00002896A (en) Vitronectin receptor antagonist
MXPA01001386A (en) Vitronectin receptor antagonists

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees